Lexicon Pharmaceuticals
LXRX
136 hedge funds and large institutions have $1.89B invested in Lexicon Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 41 increasing their positions, 47 reducing their positions, and 23 closing their positions.
634% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $2.23M
15% more capital invested
Capital invested by funds: $1.64B → $1.89B (+$252M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.3% less ownership
Funds ownership: 109.45% → 109.14% (-0.3%)
1% less funds holding
Funds holding: 137 → 136 (-1)
4% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 23
13% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIM
USS Investment Management
London,
United Kingdom
|
+$54.3M |
| 2 |
PA
Pinnacle Associates
New York
|
+$11.1M |
| 3 |
Millennium Management
New York
|
+$7.87M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.58M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$16.8M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.5M |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$7.81M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$7.38M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.12M |
LXRX Hedge Fund Activity: Q2 2017 in Review
136 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2017, worth a combined $1.89B — up 15% from $1.64B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LXRX and 22 opened new positions — a net loss of 1 holder — while 47 trimmed existing stakes and 41 added.
The largest buyer was USS Investment Management, opening a new position worth an estimated $54.3M. The largest seller was Kingdon Capital Management, cutting an estimated $16.8M.
- 136 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2017, down from 137 in Q1 2017.
- Funds reported $1.89B of Lexicon Pharmaceuticals stock for Q2 2017, up 15% quarter-over-quarter.
- 22 funds opened new Lexicon Pharmaceuticals positions in Q2 2017 and 23 closed out, a net change of -1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q2 2017 was USS Investment Management, an estimated $54.3M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2017 was Kingdon Capital Management, an estimated $16.8M sold.
Based on aggregated 13F filings for Q2 2017.